WO2013066469A3 - Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics - Google Patents
Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics Download PDFInfo
- Publication number
- WO2013066469A3 WO2013066469A3 PCT/US2012/050635 US2012050635W WO2013066469A3 WO 2013066469 A3 WO2013066469 A3 WO 2013066469A3 US 2012050635 W US2012050635 W US 2012050635W WO 2013066469 A3 WO2013066469 A3 WO 2013066469A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacterial pathogens
- lactam antibiotics
- disclosed
- sensitivity
- increasing
- Prior art date
Links
- 244000052616 bacterial pathogen Species 0.000 title abstract 4
- 239000003782 beta lactam antibiotic agent Substances 0.000 title abstract 3
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 230000035945 sensitivity Effects 0.000 title abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 239000002132 β-lactam antibiotic Substances 0.000 abstract 2
- 229940124586 β-lactam antibiotics Drugs 0.000 abstract 2
- 241000192125 Firmicutes Species 0.000 abstract 1
- 206010034133 Pathogen resistance Diseases 0.000 abstract 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Staphylococcus aureus are gram-positive bacteria that are currently the leading cause of invasive infections in humans. While antibiotic therapy is currently used to treat S. aureus infections, the emergence of antibiotic resistant strains such as those resistant to methicillan are rapidly exhausting treatment options. Disclosed herein are methods and compositions for increasing the sensitivity of bacterial pathogens to β-lactam antibiotics. Also disclosed herein are genes involved in modulating antibiotic resistance which serve as novel targets for treatments aimed at inhibiting antibiotic resistant bacterial pathogens. Also disclosed herein are kinase inhibitors which demonstrate superior activity in sensitizing bacterial pathogens to β-lactam antibiotics.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523793P | 2011-08-15 | 2011-08-15 | |
| US61/523,793 | 2011-08-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013066469A2 WO2013066469A2 (en) | 2013-05-10 |
| WO2013066469A3 true WO2013066469A3 (en) | 2013-07-04 |
Family
ID=48192985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2012/050635 WO2013066469A2 (en) | 2011-08-15 | 2012-08-13 | Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2013066469A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015075166A1 (en) * | 2013-11-22 | 2015-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of a bacterial infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060070135A1 (en) * | 1998-07-24 | 2006-03-30 | Michel Tremblay | Compositions and methods for inhibiting the enzymatic activity of PTP-1B |
| WO2007075176A1 (en) * | 2005-12-29 | 2007-07-05 | Mitsui Norin Co., Ltd | Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin |
| US20080312244A1 (en) * | 2005-07-29 | 2008-12-18 | Werner Mederski | Squaric Acid Derivatives as Protein Kinase Inhibitors |
-
2012
- 2012-08-13 WO PCT/US2012/050635 patent/WO2013066469A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060070135A1 (en) * | 1998-07-24 | 2006-03-30 | Michel Tremblay | Compositions and methods for inhibiting the enzymatic activity of PTP-1B |
| US20080312244A1 (en) * | 2005-07-29 | 2008-12-18 | Werner Mederski | Squaric Acid Derivatives as Protein Kinase Inhibitors |
| WO2007075176A1 (en) * | 2005-12-29 | 2007-07-05 | Mitsui Norin Co., Ltd | Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin |
Non-Patent Citations (2)
| Title |
|---|
| RENZONI ET AL.: "Whole Genome Sequencing and Complete Genetic Analysis Reveals Novel Pathways to Glycopeptide Resistance in Staphylococcus aureus, art e21577", PLOS ONE, vol. 6, no. 6, 27 June 2011 (2011-06-27), pages 1 - 14, XP003031273 * |
| ZAPUN ET AL.: "Penicillin-Binding Proteins and Beta-Lactam Resistance", ANTIMICROBIAL DRUG RESISTANCE, vol. 1, 2009, pages 145 - 170 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013066469A2 (en) | 2013-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013122888A3 (en) | Methods of treating bacterial infections | |
| WO2018208987A3 (en) | Antibacterial compounds | |
| WO2018208985A3 (en) | Antibacterial compounds | |
| PH12016501577A1 (en) | Monobactam organic compounds for the treatment of bacterial infections | |
| WO2016179440A3 (en) | Antimicrobial therapy | |
| AU2015205914B2 (en) | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections | |
| WO2013184755A3 (en) | Seca inhibitors and methods of making and using thereof | |
| TN2014000417A1 (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
| WO2009140215A3 (en) | Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds | |
| WO2015114666A3 (en) | Treatments for resistant acne | |
| PH12019500360A1 (en) | Antibiotic compounds | |
| WO2017017631A3 (en) | Antibacterial therapeutics and prophylactics | |
| WO2011047319A8 (en) | Antimicrobial compounds and methods of making and using the same | |
| WO2012173689A3 (en) | Antimicrobial compounds and methods of making and using the same | |
| WO2011047323A3 (en) | Antimicrobial compounds and methods of making and using the same | |
| WO2012034077A3 (en) | Compositions and methods related to attenuated staphylococcal strains | |
| ZA201100705B (en) | Antibacterial combination therapy for the treatment of gram positive bacterial infections | |
| PH12014500429A1 (en) | Antibacterial compounds and methods for use | |
| WO2012106264A3 (en) | Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections | |
| MX2011008043A (en) | Actagardine derivatives. | |
| WO2020061375A8 (en) | Antibacterial compounds | |
| EP3846616A4 (en) | Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains | |
| WO2014022382A3 (en) | Antibacterial protein kinase inhibitors | |
| WO2016108930A3 (en) | Antisense antibacterial compounds and methods | |
| AU2010306647A8 (en) | Antimicrobial compounds and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12844682 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12844682 Country of ref document: EP Kind code of ref document: A2 |